WHAT IS INTERCEPT-MDS?

EXPLORING CELL-TO-CELL HETEROGENEITY AND EXPLOITING EPIGENETIC REGULATION FOR THE INTERCEPTION OF MYELOID DISEASE CELLS

INTERCEPT-MDS is an Innovative Training Network funded by the European Union’s Horizon 2020 research and innovation programme.

Born from the LifeTime Initiative, the aim of INTERCEPT-MDS is to train Europe’s first experts at the doctorate level in the novel field of disease interception: treating a disease before it fully develops by removing altered cells.

INTERCEPT-MDS brings together 10 European public and private institutions in a European network of experts in leukaemia, epigenetics and single-cell genomics.

Through a multidisciplinary and multisectoral approach, INTERCEPT-MDS will study disease interception in the context of clonal myeloid diseases, using single-cell genomic methods to identify altered cells and test epigenetic perturbations to specifically remove them.

NEWS

1.02.2023

February is here and it’s time to feature our second ESR of the month: Ecem Kirkiz!

Ecem works in Florian Grebien’s lab at the University of Veterinary Medicine Vienna (VetMedUni) exploring the regulators of NUP98-fusion proteins, which drive disease in certain patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).

To learn more about Ecem and the research she is conducting, watch her video below. And stay tuned for more content about her during February!